Medunik Canada is pleased to announce the launch of NORD Founder Abbey Meyers’ memoir, “Orphan Drugs: A Global Crusade”

BLAINVILLE, QC (Canada) – February 16, 2016 – Medunik Canada, a Canadian pharmaceutical company specialized in orphan drugs, is pleased to announce the launch of Orphan Drugs: A Global Crusade, the memoir of Abbey Meyers, founder and past President of the National Organization for Rare Disorders (NORD). In anticipation of Rare Disease Day on February 29th, Medunik Canada would like to bring to light the hard work and commitment of orphan drug crusaders, like Ms. Meyers.

Read more

PHEBURANE® now available for distribution in Canada through Medunik Canada

BLAINVILLE, QC (Canada) – March 30th, 2015 – Medunik Canada, a Canadian pharmaceutical company specialized in rare diseases, is pleased to announce that PHEBURANE® (a tasteless oral formulation of sodium phenylbutyrate), is now available for distribution in Canada. PHEBURANE® is the first drug to be approved in Canada for the chronic management of urea cycle disorders (UCD) after receiving market authorisation on January 27th, 2015.

Read more

Medunik Canada is pleased to announce that Health Canada has granted market authorization for Pheburane®

BLAINVILLE, QC (Canada) – January 27th, 2015 – Medunik Canada, a Canadian pharmaceutical company specialized in orphan drugs, is pleased to announce that Health Canada has issued a Notice of Compliance (NOC) for PHEBURANE® (a tasteless oral formulation of sodium phenylbutyrate), indicated as adjunctive therapy in the chronic management of urea cycle disorders (UCD), involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase or argininosuccinate synthetase. Canadians living with a urea cycle disorder will now have access to an approved tasteless medication for the treatment of this metabolic disease.

Read more

Medunik Canada announces Health Canada Priority Review of PHEBURANE® indicated for the treatment of Urea Cycle Disorders (UCD)

BLAINVILLE, QC (Canada) – September 24th, 2014 – Medunik Canada, a Canadian pharmaceutical company specialized in orphan drugs, announces that PHEBURANE® (a tasteless oral formulation of sodium phenylbutyrate), indicated as adjunctive therapy in the chronic management of Urea Cycle Disorders (UCD), was granted a Priority Review Status by Health Canada. This treatment will provide Canadians living with a urea cycle disorder access to a lower-cost alternative solution for the treatment of this metabolic disease.

Read more

Medunik Canada and Lucane Pharma conclude an exclusive licence and collaboration agreement

Blainville, Quebec (Canada) – December 4, 2013 - Medunik Canada, a pharmaceutical company specialized in orphan drugs and Lucane Pharma, a French niche pharmaceutical company, announced the conclusion of an exclusive collaboration agreement. Through this agreement, Medunik Canada receives the exclusive Canadian rights to market and distribute a new therapeutic option for patients suffering from Urea Cycle Disorders (UCD), a group of rare diseases involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase or argininosuccinate sythetase. This therapeutic option is taste-free, which facilitates medication and favours compliance to treatment.

Read more